PPPM

Real World Data Indicate That Trilaciclib Reduces Hospitalizations and Myelosuppressive Events and May Improve Survival in Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Retrieved on: 
Friday, October 27, 2023
Survival, Inovalon, Patient, G1 Therapeutics, American Society of Clinical Oncology, Medicare, Thrombocytopenia, EMOL, RESEARCH, Observational study, HRU, PPPM, Aplastic anemia, ESA, Cytopenia, Society, King Fahad Specialist Hospital Dammam, RBC, Risk, G-CSF, Anemia, Therapy, Hospital, PARK, Neutropenia, ASCO, Pharmaceutical industry, Medical imaging, Health insurance, Trilaciclib

1.2% of trilaciclib-treated patients had grade ≥3 HAEs in ≥2 lineages compared to 13.5% of patients in the comparison cohort.

Key Points: 
  • 1.2% of trilaciclib-treated patients had grade ≥3 HAEs in ≥2 lineages compared to 13.5% of patients in the comparison cohort.
  • Assessment of Hospitalizations and Cytopenia Events Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Chemotherapy with Trilaciclib (Huang, H. et al.)
  • Burden of Myelosuppression in Extensive-Stage Small-Cell Lung Cancer Patients Receiving Chemotherapy: Retrospective Analysis of Real-World Data from Tennessee Oncology (Blakely, L.J.
  • These findings suggest that how patients present in their initial visits are not necessarily predictive of myelosuppressive events.

Call for Nominations: 14th Annual Privacy Papers for Policymakers

Retrieved on: 
Tuesday, September 26, 2023
FPF, Policy, PPPM, Congress, Student, Future of Privacy Forum, Research, Attention, Second Continental Congress, Solution, Privacy, Tutoring

Call for Nominations: 14th Annual Privacy Papers for Policymakers

Key Points: 
  • Call for Nominations: 14th Annual Privacy Papers for Policymakers
    The Future of Privacy Forum (FPF) invites privacy scholars and authors with an interest in privacy issues to submit finished papers to be considered for FPF’s 14th annual Privacy Papers for Policymakers (PPPM) Award.
  • The award will be given to authors who have completed or published top privacy research and analytical work in the last year that is relevant to policymakers.
  • Learn more about the Privacy Papers for Policymakers program and view previous year’s highlights and winning papers on our website.
  • FPF will invite winning authors to present their work at an annual event with top policymakers and privacy leaders in spring 2024 (date TBD).

Western State College of Law Associate Professor Eunice Park Named Future of Privacy Forum’s “Privacy Papers for Policymakers” Award-Winner

Retrieved on: 
Thursday, February 16, 2023
Legal, Technology, Professional Services, Software, Other Education, Internet, University, Data Management, Education, Woman, Park, PPPM, Future, State College, Pennsylvania, Travel, Law enforcement, Future of Privacy Forum, Second Continental Congress, Research, Privacy, Social change, Westcliff University, Mining, Congress, Student, Policy, Faculty, Law, FPF, Pharmaceutical industry

Western State College of Law at Westcliff University ’s Associate Professor Eunice Park was named a Privacy Papers for Policymakers (PPPM) award-winner by the Future of Privacy Forum (FPF) — a global non-profit focused on data protection headquartered in Washington, D.C.

Key Points: 
  • Western State College of Law at Westcliff University ’s Associate Professor Eunice Park was named a Privacy Papers for Policymakers (PPPM) award-winner by the Future of Privacy Forum (FPF) — a global non-profit focused on data protection headquartered in Washington, D.C.
  • “It is my hope that the work I created will influence relevant policymakers to institute the proper federal protections for digital health care data,” said Park.
  • “Our current laws simply don’t do enough to protect privacy.
  • “We’re incredibly proud to have gifted and passionate professors like Eunice Park as a part of our faculty,” said Allen Easley, dean of Western State.

Analysis Group Is First to Describe Economic Burden for Patients with Acute Suicidal Ideation Tied to Major Depressive Disorder

Retrieved on: 
Tuesday, April 12, 2022
Lists of diseases, Patient, Analysis Group, Major depressive disorder, Behavior, PPPM, Epidemiology, Government, MDD, Janssen, COVID-19, Adult, Population, MDSI, ED, SIB, Research, Principal investigator, Suicide, Janssen Pharmaceuticals, United States Public Health Service, Johnson & Johnson, Health, Carmine, Journal, HRU, The Journal of Clinical Psychiatry, Psychotherapy, Physician, Industry, Risk, Time, Pharmaceutical industry, Hospital, Health insurance

BOSTON , April 12, 2022 /PRNewswire/ -- Researchers from Analysis Group, a global leader in health economics and outcomes research (HEOR), and the Janssen Pharmaceutical Companies of Johnson & Johnson have authored the first study to describe the economic burden of MDSI, or diagnosed major depressive disorder (MDD) with acute suicidal ideation or behavior (SIB). The study, published in the Journal of Clinical Psychiatry, is timely given the emerging evidence of negative effects of the COVID-19 pandemic on psychological health, and underscores the need for strategies to identify and treat at-risk patients for whom personalized pharmacological and non-pharmacological therapies may prevent a crisis.   

Key Points: 
  • First-of-its-kind study describes costs associated with major depressive disorder with acute suicidal ideation.
  • Inpatient admissions were 158 times higher within 1 month following the event, and 28 times higher within 12 months.
  • Substantial economic burden associated with MDSI persisted in the 12 months following the SIB event.
  • The study, titled "Economic Burden of Commercially Insured Patients with Major Depressive Disorder and Acute Suicidal Ideation or Behavior in the United States," was published in April by the Journal of Clinical Psychiatry.

Virta Health’s Diabetes Reversal Treatment Drives Savings of More Than $10k Per Patient Over Two Years, New Analysis Shows

Retrieved on: 
Wednesday, September 15, 2021
Biotechnology, Diabetes, Hospitals, Health, Pharmaceutical, Insulin, FDA, Technology, Health, Diabetes, Conditional sentence, Type 2 diabetes, Patient, VP, Employment, Risk, American Diabetes Association, Compensation, Harvard Medical School, PPPM, Disease, Milliman, HIV disease progression rates, Policy, Physician, Medication costs, Obesity, Multimedia, Medical savings account (United States), Twitter, Analysis, Population, ROI, Health insurance, Pharmaceutical industry

Virta Health , the leader in type 2 diabetes reversal, saves payers $425 per patient per month (PPPM)more than $10k over two yearsaccording to a new internal analysis .

Key Points: 
  • Virta Health , the leader in type 2 diabetes reversal, saves payers $425 per patient per month (PPPM)more than $10k over two yearsaccording to a new internal analysis .
  • Virtas treatment flips that trend, by helping patients normalize blood sugar while often eliminating the need for diabetes medications.
  • Medication Savings: Medication elimination was the largest driver of cost savings from Virtas treatment, amounting to 45% of total savings over two years ($193 PPPM).
  • Virta reverses type 2 diabetes through innovations in technology, nutrition science, and continuous remote care from physicians and behavioral experts.

Triskell Software, recognized as a representative vendor in Gartner's 2021 Market Guide for APM Tools

Retrieved on: 
Thursday, September 2, 2021
Growth, Strategy, Research, PPM, Project portfolio management, PPPM, APM, Triskell, Solution, Project, Organization, Publication, Zhejiang Market Guide, Application portfolio management, Technology, Risk management, Software

Gartners 2021 Market Guide is a detailed research that shows the most relevant vendors that can be found in the APM tools market.

Key Points: 
  • Gartners 2021 Market Guide is a detailed research that shows the most relevant vendors that can be found in the APM tools market.
  • This is the second Market Guide where Triskell has been included by Gartner following the Strategy Execution Management Software Market Guide of 2017, 2018 and 2019.
  • As stated in this Gartner Market Guide, "Application Portfolio Management tools help business and IT stakeholders to understand the strengths and weaknesses of their application portfolio" [1].
  • [1] Gartner, "Market Guide for Application Portfolio Management Tools", Stefan Van Der Zijden, Wan Fui Chan, 24 August 2021.

Triskell Software, recognized as a representative vendor in Gartner's 2021 Market Guide for APM Tools

Retrieved on: 
Thursday, September 2, 2021
Growth, Strategy, Research, PPM, Project portfolio management, PPPM, APM, Triskell, Solution, Project, Organization, Publication, Zhejiang Market Guide, Application portfolio management, Technology, Risk management, Software

Gartners 2021 Market Guide is a detailed research that shows the most relevant vendors that can be found in the APM tools market.

Key Points: 
  • Gartners 2021 Market Guide is a detailed research that shows the most relevant vendors that can be found in the APM tools market.
  • This is the second Market Guide where Triskell has been included by Gartner following the Strategy Execution Management Software Market Guide of 2017, 2018 and 2019.
  • As stated in this Gartner Market Guide, "Application Portfolio Management tools help business and IT stakeholders to understand the strengths and weaknesses of their application portfolio" [1].
  • [1] Gartner, "Market Guide for Application Portfolio Management Tools", Stefan Van Der Zijden, Wan Fui Chan, 24 August 2021.